In-situ formable dextran/chitosan-based hydrogels functionalized with collagen and EGF for diabetic wounds healing

Biomater Adv. 2022 May:136:212773. doi: 10.1016/j.bioadv.2022.212773. Epub 2022 Mar 25.

Abstract

Delayed or non-healing skin wounds causing gangrene or even amputation, greatly threats diabetic patients lives. Herein, a bioactive, in-situ formable hydrogel based wound dressing was designed through simple Schiff base reaction. Oxidized dextran (OD) and carboxyethyl chitosan (CEC) were crosslinked together and applied as the main porous framework of hydrogel. To improve the mechanical strength and biocompatibility, collagen (Col) and EGF (Epidermal Growth Factor) were introduced into OD-CEC precursors: (1) after addition of only Col, the mechanical strength of hydrogels was improved by participating the functional -NH2 group of Col into the crosslinking process. Moreover, swelling ratio was as high as 750% on 3%OD-3%CEC-Col (water retention rate was 65 wt% after 7 days). (2) Once we introduced both Col and EGF into the OD-CEC hydrogel, the proliferation of mouse embryonic fibroblast (NIH 3T3) cells was promoted using 3%OD-3%CEC-Col/EGF, an accelerated wound healing was observed with 86% wound closure after only 14 operative days. Hematoxylin and eosin (H&E) staining and Masson staining indicated the synergy of Col and EGF might promote new tissue's formation, well collagen distributions and thus accelerate skin regeneration, presenting great potentials in wound healing of diabetic patients.

Keywords: Carboxyethyl chitosan; Collagen; Diabetic wound repair; EGF; In-situ formable hydrogel; Oxidized dextran.

MeSH terms

  • Animals
  • Chitosan* / pharmacology
  • Collagen / pharmacology
  • Dextrans / pharmacology
  • Diabetes Mellitus* / drug therapy
  • Epidermal Growth Factor / pharmacology
  • Fibroblasts
  • Hydrogels / pharmacology
  • Mice
  • Wound Healing

Substances

  • Dextrans
  • Hydrogels
  • Epidermal Growth Factor
  • Collagen
  • Chitosan